Clementia is a biopharmaceutical company dedicated to bringing effective new treatments to people who have none.
We are rapidly developing our first lead product candidate, palovarotene, to treat fibrodysplasia ossificans progressiva (FOP), an ultra-rare and severely disabling disorder, and other diseases.
We believe that palovarotene holds significant potential for individuals with FOP and are currently investigating the oral compound in Phase 2 clinical trials. We strive to work with bold efficiency and hand-in-hand with physicians and disease communities to chart a new course in drug development.
|New Enterprise Associates, Janus Capital Group, UCB Pharma, RA Capital Management, Rock Springs Capital, EcoR1 Capital, OrbiMed, BDC Healthcare Venture|
When was Clementia Pharmaceuticals founded?
Clementia Pharmaceuticals was founded in 2012.
Who are Clementia Pharmaceuticals key executives?
Clementia Pharmaceuticals's key executives are Clarissa Desjardins, Jeff Packman and James M. Roach.
Who are Clementia Pharmaceuticals competitors?
Competitors of Clementia Pharmaceuticals include International Stem Cell Corporation, Innate Pharma and DBV Technologies.
Where is Clementia Pharmaceuticals headquarters?
Clementia Pharmaceuticals headquarters is located at 1000 De La Gauchetière, 1000 Rue de la Gauchetière O #1200, Montréal.
Where are Clementia Pharmaceuticals offices?
Clementia Pharmaceuticals has offices in Montréal and Newton.
How many offices does Clementia Pharmaceuticals have?
Clementia Pharmaceuticals has 2 offices.
Receive alerts for 300+ data fields across thousands of companies